Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy

L. Milazzo, M. Corbellino, A. Foschi, V. Micheli, A. Dodero, A. Mazzocchi, V. Montefusco, G. Zehender, S. Antinori

Research output: Contribution to journalArticle

Abstract

Prophylaxis with lamivudine (LAM) is recommended for hepatitis B core antibody-positive allogenic hematopoietic stem cell transplant (HSCT) recipients, but the optimal timing for the institution and duration of the prophylaxis is still unknown. Furthermore, considering the high rate of mortality associated with hepatitis B virus reactivation (HBV-R), the most potent and long-term effective antiviral regimen should be considered. We report here a case of late onset of HBV-R after a long-term prophylaxis with LAM in a patient who underwent HSCT for non-Hodgkin lymphoma and who was successfully treated with a combination antiviral regimen including entecavir and tenofovir disoproxil fumarate.

Original languageEnglish
Pages (from-to)95-98
Number of pages4
JournalTransplant Infectious Disease
Volume14
Issue number1
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Allogeneic hematopoietic stem cell transplant
  • Entecavir
  • HBV reactivation
  • Hepatitis B virus
  • Tenofovir

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy'. Together they form a unique fingerprint.

  • Cite this